Gilbert Christopher R, Shojaee Samira, Maldonado Fabien, Yarmus Lonny B, Bedawi Eihab, Feller-Kopman David, Rahman Najib M, Akulian Jason A, Gorden Jed A
Thoracic Surgery and Interventional Pulmonology, Swedish Cancer Institute, Seattle, WA.
Division of Pulmonary Disease and Critical Care Medicine, Virginia Commonwealth University, Richmond, VA.
Chest. 2022 Jan;161(1):276-283. doi: 10.1016/j.chest.2021.08.043. Epub 2021 Aug 12.
Hepatic hydrothorax can be present in 5% to 15% of patients with underlying cirrhosis and portal hypertension, often reflecting advanced liver disease. Its impact can be variable, because patients may have small pleural effusions and minimal pulmonary symptoms or massive pleural effusions and respiratory failure. Management of hepatic hydrothorax can be difficult because these patients often have a number of comorbidities and potential for complications. Minimal high-quality data are available for guidance specifically related to hepatic hydrothorax, potentially resulting in pulmonary or critical care physician struggling for best management options. We therefore provide a Case-based presentation with management options based on currently available data and opinion. We discuss the role of pleural interventions, including thoracentesis, tube thoracostomy, indwelling tunneled pleural catheter, pleurodesis, and surgical interventions. In general, we recommend that management be conducted within a multidisciplinary team including pulmonology, hepatology, and transplant surgery. Patients with refractory hepatic hydrothorax that are not transplant candidates should be managed with palliative intent; we suggest indwelling tunneled pleural catheter placement unless otherwise contraindicated. For patients with unclear or incomplete hepatology treatment plans or those unable to undergo more definitive procedures, we recommend serial thoracentesis. In patients who are transplant candidates, we often consider serial thoracentesis as a standard treatment, while also evaluating the role indwelling tunneled pleural catheter placement may play within the course of disease and transplant evaluation.
肝性胸水可见于5%至15%的潜在肝硬化和门静脉高压患者,常提示肝病晚期。其影响因人而异,因为患者可能有少量胸腔积液和轻微肺部症状,也可能有大量胸腔积液和呼吸衰竭。肝性胸水的管理可能很困难,因为这些患者通常有多种合并症和并发症风险。目前几乎没有高质量的数据可专门指导肝性胸水的治疗,这可能导致肺科或重症监护医生难以抉择最佳治疗方案。因此,我们根据现有数据和观点,通过病例展示治疗方案。我们讨论胸腔干预措施的作用,包括胸腔穿刺术、胸腔闭式引流术、留置隧道式胸腔导管、胸膜固定术和外科手术干预。一般来说,我们建议在包括肺病科、肝病科和移植外科的多学科团队内进行管理。对于不符合移植条件的难治性肝性胸水患者,应采取姑息治疗;若无禁忌,我们建议放置留置隧道式胸腔导管。对于肝病治疗计划不明确或不完整的患者,或无法接受更确定性治疗的患者,我们建议进行胸腔穿刺抽液术。对于符合移植条件的患者,我们通常将胸腔穿刺抽液术作为标准治疗方法,同时评估留置隧道式胸腔导管在疾病进程和移植评估中可能发挥的作用。